If B is helpful with C only, the company will be worth a fortune. Adding in other viruses? To infinity and beyond. Still hoping it pans out, but they are losing time, and need to start the trial. To do that they need to publish the data, pre- pub just fine, while we wait for peer review. Is a grant still possible? For other viruses ? After initial paper(s) out? I am nervous as we all are that q 4 will slip for the trial, just Sept slipped for the paper. Very hard to be confident in IP-
Tamiflu a famous low bar, agreed